Clinical trials are about to begin where embryonic stem cells will be injected into the eyes of people with Stargardt’s macular degeneration.
Robert Lanza, the company’s chief scientific officer, said that the first patient could receive the stem cell transplants early in the new year and although the trial is designed primarily to assess safety, the first signs of visual improvement may be apparent within weeks. “Talking to the clinicians, we could see something in six weeks, that’s when we think we may see some improvements. It really depends on individual patients but that’s a reasonable time frame when something may start to happen,” Dr Lanza said.
The New Yorker has a long profile of Francis Collins, the ardent Christian whom Obama picked to head up the NIH, and the NIH’s role in embryonic stem cell research.
A year later, Obama’s appointment of Collins seemed an inspired choice. The President had found not only a man who reflected his own view of the harmony between science and faith but an evangelical Christian who hoped that the government’s expansion of embryonic-stem-cell research might bring the culture war over science to a quiet end. On August 23rd, however, Judge Royce C. Lamberth, of the Federal District Court for the District of Columbia, halted federal spending for embryonic-stem-cell research, putting hundreds of research projects in limbo and plunging the N.I.H. back into a newly contentious national debate.